Back to Search Start Over

1.5 Efficacy and Safety of Dulaglutide vs. Metformin in Type 2 Diabetes (AWARD-3) (69-OR)

Authors :
Guillermo E. Umpierrez
Santiago Tofe Povedano
Valeria Pechtner
Federico Pérez Manghi
Linda Shurzinske
Source :
Nederlands Tijdschrift voor Diabetologie. 11:78-78
Publication Year :
2013
Publisher :
Springer Science and Business Media LLC, 2013.

Abstract

This Phase 3, randomized, double-blind, parallel-arm, monotherapy study compared the efficacy and safety of 2 doses of dulaglutide (DU), a long-acting GLP-1-receptor agonist, to metformin (MET) in patients with early type 2 diabetes (mean 2.6 years) treated with diet and exercise alone or in combination with 1 oral antidiabetic medication (low dose for ≥ 3 months before screening).

Details

ISSN :
18766242 and 15672743
Volume :
11
Database :
OpenAIRE
Journal :
Nederlands Tijdschrift voor Diabetologie
Accession number :
edsair.doi...........a48eaba7a29fce764595c17d97a80849
Full Text :
https://doi.org/10.1007/s12467-013-0030-x